Vincent Picozzi, MD, discusses the PANOVA-3 data supporting the approval of Optune Pax and the future of TTFields in pancreatic cancer.
Understanding Tumor Treating Fields as a Novel Modality in Pancreatic Cancer
Vincent Picozzi, MD, discusses the FDA approval of Optune Pax for locally advanced pancreatic cancer and the criteria for optimal patient selection.
Advertisement
Advertisement
Trending on OncLive
1
ctDNA MRD Status Predicts OS Benefit With Adjuvant Chemotherapy in Resected CRC Liver Metastases
2
Cracking the KRAS Code: How Daraxonrasib Is Reshaping Pancreatic Cancer and Beyond
3
FDA Accepts NDA for Varegacestat in Desmoid Tumors
4
INCB123667 Advances to Phase 3 Following Encouraging Activity in Platinum-Resistant Ovarian Cancer
5